Dassault Systèmes acquires Medidata to enforce its position in Healthcare.

 

 

Btobioinnovation.com

 

Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation  jcm9144@gmail.com

 

 

SPECIAL REPORT #25

 

 

Dassault Systèmes acquires Medidata to enforce its position in Healthcare.

 

 

On June 12, Dassault Systèmes (Paris, France) announced the acquisition on Medidata (New York, USA) for $5.8 billion, to accelerate the Healthcare industry innovation through an end-to-end collaboration platform.

In a video broadcasted on Wednesday, Bernard Charlès, Dassault Systèmes’ CEO, announced: “Today marks a significant milestone for the Life Sciences industry and the value of the virtual world to address the complexity of developing personalized and patient-centric experiences. Multidiscipline scientific innovation and industrial performance call for a platform connecting the dots between people, idea and data”. The deal with Medidata is the largest acquisition ever made by Dassault Systèmes who has signed a financial agreement with a bank consortium in order to raise €4 billion to complete the operation.

Medidata is already the world leader in eClinical solutions for more than 1,300 customers worldwide, solutions that reduce risks in clinical trials for pharmaceutical and biotechnology companies as well as for CRO’s.  In many hospitals where clinical trials are being performed the Medidata platform is already installed and connects and consolidates all information related to a given trial or a given subject. Clinical trials are a critical step for the biopharmaceutical industry and amount to two third of the costs and represent more than half of the time needed to develop and launch a new therapeutic solution. Digital solutions are expected to increase clinical trial productivity by as far as 30%. Medidata reported $636 million sales in 2018 and Charlès expects Dassault Systèmes to exceed $1 billion sales in the Healthcare sector in 2019. “With the join forces of Medidata we are entering the hospitals” said Charlès. Data mining of clinical trials is still an emerging business but is estimated to reach $4 billion in 2025 according to Frost & Sullivan.

 

Dassaults Systèmes, the 3DEXPERIENCE company is the world-leader in proposing solutions that transform the way products are designed, produced and supported in area such as the automobile, the plane, the mining and the healthcare industries. The company provides its solutions to over 250,000 customers in more than 140 countries.

 

Other major players in the eClinical field are: BioClinica, Datatrack International, ERT, MedNet Solutions, Parexel International and Google through Verily who recently announced a major consortium agreement with Novartis, Pfizer, Otsuka and Sanofi.

 

 

 

 

 

 

This document has been prepared by btobioinnovation and is provided to you for information purposes only.  The information contained in this document has been obtained from sources that btobioinnovation believes are reliable but btobioinnovation does not warrant that it is accurate or complete. The views presented in this document are those of btobioinnovation’s editor at the time of writing and are subject to change.  btobioinnovation has no obligation to update its opinions or the information in this document.

 

 

Share :
  •  
  •  
  •  
  •  
  •